Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02177695 · ClinicalTrials.gov registry record · Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT02177695 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 237 participants.
The verdict
NCT02177695, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Gemcitabine
- DRUG Methotrexate
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2014-08-28 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02177695
The ClinicalTrials.gov registry entry for NCT02177695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02177695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02177695 about?
NCT02177695 is a clinical study titled "S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer". The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
What is the current status of trial NCT02177695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2014-08-28. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT02177695?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Gemcitabine (DRUG), Methotrexate (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02177695?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.